Breast cancer is the one common cancer where a PET CT is often not the right next scan — and where being told you do not need one can be as important as being told you do.
That is an unusual thing for a diagnostic centre to write. But it is the honest position, and it matters, because families who have read about PET scans frequently arrive asking for one when their surgeon has quite deliberately not ordered it.
This guide explains when PET CT genuinely adds something in breast cancer, when mammography, ultrasound or MRI answer the question better, why very early-stage disease usually does not need a PET, how treatment response is assessed, and what to ask before you book anything.
Start here: PET is not a breast imaging test
The most common misunderstanding is that a PET CT is a more advanced way of looking at the breast itself. It is not.
For the breast, the established tools are mammography, ultrasound and breast MRI. They show structure, calcifications, margins and soft tissue detail at a level of spatial resolution a PET CT does not attempt. A PET is a whole-body metabolic survey — it looks at the entire body coarsely rather than the breast finely.
So a PET CT is not ordered to characterise a lump, to assess a mammographic abnormality, or to plan breast surgery. It is ordered to answer a different question: has anything travelled elsewhere in the body, and is the treatment working?
Once that distinction is clear, the rest of this page follows.
When a PET CT genuinely adds something
Staging in locally advanced or higher-risk disease
Where the tumour is large, where multiple lymph nodes appear involved, or where the clinical picture suggests a higher risk of disease having spread, a whole-body survey has real value. It can identify bone, liver, lung or distant nodal involvement that would change the entire treatment approach.
This is the main staging use, and it is the one your oncologist weighs.
Inflammatory breast cancer
An aggressive presentation where whole-body assessment is generally considered important from the outset.
Assessing response to neoadjuvant chemotherapy
Where chemotherapy is given before surgery to shrink the tumour, the team needs to know whether it is working. Metabolic change often precedes measurable size change, which is why a functional assessment is useful here.
Suspected recurrence
When a tumour marker rises, a symptom appears, or another investigation shows something equivocal, a whole-body PET can map where disease has returned.
Where conventional imaging is equivocal
A bone scan showing an uncertain area, a CT showing an indeterminate liver lesion — situations where an additional functional assessment helps resolve the question.
Suspected metastatic disease at presentation
Where symptoms or blood results suggest disease may already be widespread.
When a PET CT is usually not needed — and why that is good news
This section will save some readers a considerable amount of money and worry.
In early-stage breast cancer, routine PET CT staging is generally not recommended.
The reasoning is straightforward. In small tumours with limited or no nodal involvement, the likelihood of distant metastatic disease is low. When you scan a large number of such patients, the number of genuinely useful findings is small, while the number of incidental findings — benign spots that are metabolically active for entirely innocent reasons — is not.
Each of those incidental findings then generates further scans, further waiting, sometimes a biopsy, and a great deal of anxiety. For most early-stage patients, that trade is not worth making.
So if your surgeon has said a PET is not required, that is very often a considered decision reflecting good practice, not an oversight or a cost-saving measure. It is a reasonable thing to ask about — “is a PET needed in my case, or would it add more uncertainty than information?” — and most surgeons will explain their reasoning readily.
Where PET has real limitations in breast cancer
Being clear about these protects you from misreading a report.
Small tumours and low-grade disease
Very small lesions may fall below the resolution at which uptake is reliably assessed. Low-grade, slow-growing tumours may show limited uptake regardless of size.
Lobular carcinoma
Invasive lobular carcinoma frequently shows lower FDG uptake than ductal carcinoma. It also grows in a diffuse, infiltrative pattern rather than forming a discrete mass, which makes it harder to see on any imaging. A PET that looks unremarkable in lobular disease should be read with that in mind — and your team will.
Sentinel node assessment
PET does not replace sentinel lymph node biopsy. Small volumes of disease within a normal-sized node are below what any scan can reliably detect. Where axillary staging matters, the surgical procedure remains the answer.
Sclerotic bone lesions
Some treated or densely sclerotic bone lesions show low FDG uptake. A bone scan or CT appearance may carry more weight in that situation.
The brain
The standard protocol covers skull base to mid-thigh, and the brain’s naturally intense glucose uptake makes FDG a poor tool for detecting brain metastases in any case. Brain assessment is done with contrast-enhanced MRI, ordered separately when clinically indicated.
PET and breast MRI answer different questions
| Breast MRI | PET CT | |
|---|---|---|
| Looks at | The breast and axilla in fine detail | The whole body, metabolically |
| Best for | Extent of disease within the breast, multifocal disease, dense breasts, implant assessment, surgical planning | Distant spread, response assessment, suspected recurrence |
| Radiation | None | Yes, from tracer and CT |
| Typical role | Local staging | Systemic staging |
They are not alternatives. In higher-risk disease a patient may reasonably have both, answering local and systemic questions respectively. If your team has asked for both, that is why.
Practical points specific to breast PET scans
Recent breast surgery or biopsy
Surgical sites, biopsy tracks and healing tissue take up FDG. Tell the centre the date of any recent procedure so the reporting physician can account for it.
Recent vaccination
This one causes genuine confusion in breast cancer imaging. A vaccine can produce reactive uptake in the axillary lymph nodes on the side of the injection — the same nodes being assessed for cancer spread.
Tell the centre if you have been vaccinated recently, and in which arm. If you have a vaccination coming up and a scan scheduled, mention both to your treating team, who may prefer a particular sequence or a particular arm.
Breastfeeding
Lactating breast tissue takes up FDG intensely. If you are breastfeeding, this must be discussed before the scan is scheduled — both for interpretation and for the precautions that follow the tracer injection.
Positioning
Arms are usually raised above the head for the acquisition. If you have had axillary surgery, shoulder stiffness, lymphoedema or pain that makes this difficult, say so before you are positioned rather than trying to endure it. Alternatives exist, and a scan acquired while you are in pain is a scan you may have moved during.
Hormonal therapy and steroids
Mention what you are taking. Steroids in particular can raise blood sugar, which is relevant both to scheduling and to image quality.
Implants and expanders
Tell the centre. It does not usually prevent the scan, but it is relevant to positioning and interpretation.
Preparation
- Fasting — usually around 6 hours. Plain water allowed and encouraged. No tea, coffee, juice, sweets or chewing gum
- Blood sugar — checked before injection. Diabetic patients should mention it at booking; do not skip medication on your own initiative
- No strenuous exercise for around 24 hours beforehand
- Stay warm — cold activates brown fat in the neck, above the collarbones and around the upper chest, precisely where nodes are being assessed
- Quiet uptake period — 45 to 60 minutes of stillness, minimal talking
- Tell the centre if pregnant, or if there is any possibility of pregnancy, before anything is injected
What to bring
- The prescription, with the clinical indication written on it
- Mammogram, breast ultrasound and breast MRI reports and films
- Biopsy and histopathology reports, including receptor status (ER, PR, HER2)
- Previous PET, CT and bone scan studies — films or CD
- Details of any recent surgery or biopsy, with dates
- A list of current medications, including hormonal therapy and steroids
- Insurance or reimbursement papers, if you plan to file a claim
- Photo identification
Receptor status is worth carrying because it is part of the clinical context in which the images are read.
Reading the report
A breast PET report describes the primary site if still present, the axillary and other regional nodes, and then surveys the rest of the body — bones, liver, lungs and distant nodes in particular, because those are the common sites of spread in breast cancer.
SUVmax measures tracer accumulation adjusted for dose and body weight. Higher generally indicates more metabolic activity, but it is not a cancer score: inflammation, infection and healing tissue raise it, and lobular and low-grade tumours may show low uptake. It carries most meaning when compared against a previous scan.
Bone findings deserve a note. Breast cancer commonly involves bone, and PET, bone scan and CT each see bone lesions somewhat differently. Your oncologist reads them together rather than relying on one.
The impression is the reporting physician’s summary and the part your treating doctor reads first.
If your report mentions an incidental finding — a small spot somewhere unrelated — do not assume the worst. Ask your oncologist what it means in your context. Many are benign, and the section above on early-stage staging explains why they are one of the reasons routine scanning is not recommended in low-risk disease.
Radiation and safety
A PET CT involves ionising radiation from the tracer and the CT component, which is why it is prescribed for specific clinical questions rather than used as a check-up. Fluorine-18 has a half-life of under two hours, and essentially none remains active by the following day.
Precautions are simple and temporary: drink water, and keep some distance from pregnant women and young children for the rest of the day.
If you are pregnant, breastfeeding, or might be pregnant, this must be discussed before the scan is scheduled.
What decides the cost
Breast studies are usually FDG whole body, which is Rs 7,999 all-inclusive — the figure includes the scan, the tracer and the reporting, and nothing is added at the counter. Contrast or additional views are occasionally required by the protocol; send the prescription and we will confirm the complete figure for your exact study in writing.
If your team has also asked for a breast MRI or a bone scan, those are separate investigations with their own costs — worth clarifying early so nothing arrives as a surprise.
Ask these before you book
- Is the tracer included in the figure you quoted?
- Is contrast included, if my protocol requires it?
- Is reporting included?
- What is the total I will pay at the counter? In writing.
- Will my mammogram, ultrasound, MRI and previous scans be compared?
- When will the report be ready, and can it be before my appointment on [date]?
- Who reports the study, and what are their qualifications?
Before booking, one question for your surgeon or oncologist
Given how often PET is not required in early breast cancer, this is worth asking directly:
“Is a PET CT needed in my case, or would conventional imaging answer the question?”
If the answer is that it is not needed, that is a good outcome — less radiation, less cost, fewer incidental findings to chase. If the answer is that it is needed, you will understand exactly what it is for, which makes the whole appointment easier.
Where Neurad fits
Neurad Diagnostic and Healthcare LLP is a dedicated PET-CT and nuclear medicine centre at B-3, opposite Metro Pillar No. 233, near Paschim Vihar West Metro Station, New Multan Nagar, Paschim Vihar, New Delhi-110056. Monday to Saturday, 8:00 AM to 5:00 PM.
Reported by our own nuclear medicine team, not outsourced.
Your mammogram, ultrasound, MRI and previous scans compared, provided you bring them.
Written preparation instructions specific to your study, sent when you book — including the reminder about recent vaccination and which arm, which matters more in breast imaging than most patients realise.
Positioning handled with care if you have had axillary surgery, lymphoedema or shoulder restriction. Tell us at booking and we will plan for it.
Blood sugar checked before injection as standard, with diabetic patients and patients on steroids planned in advance.
Image-guided FNAC and biopsy available, so where tissue confirmation is needed it can often be arranged without another centre and another journey.
Complimentary pickup and drop within 3 km; beyond that, Rs 50 per km.
The all-inclusive figure in writing before you book.
And if your surgeon has not asked for a PET, we will say so rather than scanning you. Bring the prescription and we will tell you what it actually says.
Frequently asked questions
Do I need a PET CT for early breast cancer?
Usually not. In early-stage disease with small tumours and limited nodal involvement, routine PET staging is generally not recommended, because the chance of finding genuine distant disease is low while incidental findings are relatively common. Ask your surgeon whether it is needed in your specific case.
Can a PET scan detect breast cancer?
PET is not a breast imaging test. Mammography, ultrasound and breast MRI assess the breast itself. PET is a whole-body metabolic survey used for staging, response assessment and suspected recurrence.
Is PET better than a breast MRI?
They answer different questions. MRI assesses the extent of disease within the breast in fine detail; PET assesses the whole body metabolically. In higher-risk disease, a patient may reasonably have both.
Can a PET scan replace a sentinel lymph node biopsy?
No. Small volumes of disease within a normal-sized node are below what any scan can reliably detect. Where axillary staging matters, the surgical procedure remains the answer.
I have lobular breast cancer. Is PET reliable?
Invasive lobular carcinoma often shows lower FDG uptake than ductal carcinoma and grows in a diffuse pattern that is harder to see on any imaging. Your team reads a PET in lobular disease with that in mind, and may rely more on other investigations.
I had a vaccination recently. Does it matter?
Yes, and it is worth mentioning specifically. A vaccine can cause reactive uptake in the axillary nodes on that side — the same nodes being assessed for cancer spread. Tell the centre that you were vaccinated and in which arm.
I am breastfeeding. Can I have a PET scan?
This must be discussed before the scan is scheduled. Lactating breast tissue takes up the tracer intensely, and there are precautions that follow the injection. Raise it at booking, not on the day.
Will I have to raise my arms? I have had axillary surgery.
Arms are usually raised for the acquisition, but tell the centre at booking if you have had axillary surgery, lymphoedema, shoulder stiffness or pain. Positioning can be adapted. A scan taken while you are uncomfortable is a scan you may have moved during.
Does a whole body PET include my brain?
Generally not as a dedicated study, and FDG is a poor tool for brain metastases in any case because normal brain tissue takes up glucose intensely. Brain assessment is done with contrast-enhanced MRI when clinically indicated.
My report mentions a small incidental finding. Should I worry?
Ask your oncologist rather than assuming. Many incidental findings are benign, and they are one of the reasons routine scanning is not recommended in low-risk disease. Your treating doctor reads it in the context of everything else known about your case.
Should I bring my receptor status report?
Yes. ER, PR and HER2 status is part of the clinical context in which the images are interpreted, along with your mammogram, ultrasound and any previous scans.
What does a breast PET CT cost?
FDG whole body is Rs 7,999 all-inclusive, covering the scan, the tracer and the reporting. Contrast or additional views are occasionally required by the protocol; send the prescription on WhatsApp and we will confirm the complete figure for your exact study in writing before you book.
Do I need a prescription?
Yes. A valid prescription is required for all PET CT studies, and it should state the clinical indication.
Related reading
- PET CT for ovarian cancer — rising CA-125, and what a clear scan does not prove
- PET CT for cervical cancer — para-aortic nodes and the bladder problem in pelvic imaging
- PET CT vs CT vs MRI — why MRI is the breast imaging test, not PET
- PET CT scan price in Delhi — what decides your figure, and the nine questions to ask
Booking your scan
Send a photograph of the prescription to 8368225620 on WhatsApp. Include three things: the date of any recent surgery or biopsy, whether you have been vaccinated recently and in which arm, and whether you have any shoulder or arm restriction that affects positioning.
You will get the all-inclusive rate, the next available slot, the written preparation instructions, and a note on which previous imaging to carry.
Prefer to speak to someone? Call 8368225620 or 7011968879, Monday to Saturday, 8:00 AM to 5:00 PM.
This page is general information about the role of PET CT in breast cancer. It is not medical advice and must not be used to interpret your own report, or to request or decline a scan. Whether a PET CT is appropriate in your case is a clinical decision made by your treating surgeon or oncologist. A valid prescription is required for all PET CT studies.